Prana Biotechnology has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases.
The company listed on the Australian Stock Exchange (ASX code PBT) in March 2000 and listed on the NASDAQ (code PRAN) in September 2002.
Board
Prana has a well established Board of Directors with extensive experience in the research, pharmaceutical and financial industries.
Mr Geoffrey Kempler Executive Chairman
Dr George Mihaly Non-Executive Director
Mr Brian Meltzer Non-Executive Director
Mr Peter Marks Non-Executive Director
Research and Development Advisory Board
The Research and Development Advisory Board is composed of scientists with professional expertise in research. These scientific advisors provide advice regarding the Company‘s proposed research and development activities
Dr. Jeffrey Cummings (Chairman) UCLA Alzheimer‘s Disease Center
Dr. Craig W.Ritchie Imperial College London
Dr. Steven Targum Oxford Bioscience Partners
Professor Jean-Marc Orgogozo University of Bordeaux
Professor Ashley Bush Mental Health Research Institute
Professor Colin Masters The University of Melbourne
Professor Rudolph Tanzi Harvard Medical School, Massachusetts General Hospital
Company Secretary
Mr Richard Revelins
Special Consultants
Dr Axel Unterbeck Chief Strategic Advisor
Dr. Steven D. Targum Chief Medical Advisor
